TRDA earnings analysis
What we found in TRDA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Entrada's Q2 2026 revenue was $0.898 million, 2.6% above Q1 but 53.9% below Q2 2025, reflecting the sharp reduction in Vertex collaboration revenue after prior research-plan completion. Operating expenses declined year over year and net loss modestly narrowed to $42.763 million, but the business remains deeply loss-making, with $74.158 million of six-month operating cash burn. The central positive is encouraging, but early and post-hoc, ENTR-601-44 Cohort 1 functional data; the investment case remains dependent on upcoming October 2026 through Q1 2027 clinical readouts and the stated $223.0 million cash runway into Q3 2027.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue stabilized sequentially, down sharply YoY
- Q2 collaboration revenue was $898,000, up $23,000, or 2.6%, from the implied Q1 2026 level of $875,000, although it was down $1.052 million, or 53.9%, from $1.950 million in Q2 2025. With no cost of revenue reported, gross margin remained 100.0%.
- Year-over-year cost discipline
- Operating loss narrowed $1.886 million year over year to $44.963 million from $46.849 million as total operating expenses fell $2.938 million to $45.861 million. The operating margin nevertheless worsened sequentially to approximately -5,007% from approximately -4,835% in Q1 because revenue remains minimal.
- Net loss modestly improved year over year
- Net loss narrowed by $340,000 year over year to $42.763 million from $43.103 million in Q2 2025. The filing did not disclose quarterly EPS in the extracted financial statements.
- Early ENTR-601-44 functional signal
- The ELEVATE-44-201 Cohort 1 readout reported a 2.40-second statistically significant improvement in Time to Rise versus placebo and a 0.09 rises/second improvement in Time-to-Rise velocity; treated patients showed a 2.36% mean dystrophin increase over a 4.00% baseline.
- Cash runway extends into Q3 2027
- Liquidity was $223.0 million in cash, cash equivalents and marketable securities at June 30, 2026, which management believes funds operations into Q3 2027. The company also retains a $150.0 million ATM program, with no sales under it during Q2.
- Direct pipeline investment increased
- Six-month R&D expense declined $1.528 million to $68.423 million, despite $4.5 million higher direct R&D spending as DMD and ocular programs advanced; lower unallocated personnel and facility costs offset this investment.
- Cash burn increased year over year
- Operating cash use was $74.158 million in the first six months of 2026, up $6.162 million, or 9.1%, from $67.996 million a year earlier. Capex/free cash flow was not separately disclosed for the 2026 period.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Vertex revenue step-down remains material
- Collaboration revenue fell $20.735 million to $1.773 million for the first six months of 2026 from $22.508 million in the prior-year period, primarily because the VX-670 research-plan activities were substantially completed in Q1 2025. Revenue remains dependent on the Vertex agreement rather than product sales.
- Losses and future financing need
- The company recorded a $82.480 million six-month net loss and had a $355.6 million accumulated deficit at June 30, 2026. It expects operating losses and negative operating cash flow for the foreseeable future and will need additional capital beyond its stated Q3 2027 runway.
- Small, post-hoc clinical data set
- The most favorable ENTR-601-44 data were generated in Cohort 1 of only eight DMD participants, at 6 mg/kg, and the reported functional analyses were post hoc. The company also disclosed lower-than-expected plasma Cmax and AUC versus the prior healthy-volunteer study.
- Supply-chain and BIOSECURE exposure
- The filing newly emphasizes implementation uncertainty around the BIOSECURE Act enacted on December 18, 2025, which can restrict certain U.S. federal procurement and funding involving designated biotechnology providers. The company notes possible downstream supply-chain disruptions, particularly where China-based vendors are used.
- FDA pathway and clinical-hold risk
- The risk factors highlight uncertainty in the FDA's evolving one-pivotal-trial policy: FDA issued revised draft guidance in June 2026, but retains discretion to require additional studies. ENTR-601-44 was previously on FDA clinical hold until February 2025, demonstrating regulatory-timeline sensitivity.
- Runway dependent on spending assumptions
- Cash, equivalents and marketable securities totaled $223.0 million at June 30, 2026, while the company used $74.158 million in operating cash during the first six months. A faster-than-expected burn or clinical expansion could bring forward use of the $150.0 million ATM and create shareholder dilution.
What they reported.
What the company itself reported, taken out of the document.
- Gross margin
- 100.0%
- Operating margin
- -5007.0%
- Segment
- Collaboration revenue (Vertex): $898,000
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management expects June 30, 2026 cash, cash equivalents and marketable securities of $223.0 million to fund operations into Q3 2027; planned catalysts include ENTR-601-45 Cohort 1 data in October 2026, additional ENTR-601-44 Cohort 1 open-label data by year-end 2026, ENTR-601-44 Cohort 2 topline data in Q1 2027, and Vertex VX-670 results in H2 2026.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Entrada Therapeutics reported a significant decline in revenue for Q1 2026, generating $875,000 down from $20.6 million in Q1 2025, while net loss widened to $39.7 million versus $17.3 million last year. Cash reserves…
- 10-K · February 26, 2026
- Entrada Therapeutics, a clinical-stage biopharmaceutical company focusing on genetic medicines, has reported a significant decrease in collaboration revenue, totaling $25.4 million in 2025 compared to $210.8 million in…
- 10-Q · November 6, 2025
- Entrada Therapeutics experienced a dramatic decline in both revenue and EPS in Q3 2025. Revenue fell to $1.614 million, a decrease of $17.956 million compared to the prior year, while EPS dropped to -$1.06 from -0.35,…
- 10-Q · August 6, 2025
- TRDA reported a substantial decline in revenue and a widening loss in Q2 2025, with revenue falling to $1.95 million, down from $94.69 million YOY. The company also reported a larger EPS loss of -$1.04 vs. -0.42 in Q1…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TRDA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever